Show simple item record

dc.contributor.authorIto, Yasushi
dc.contributor.authorKelliher, Michelle A.
dc.contributor.authorYuan, Junying
dc.date2022-08-11T08:09:20.000
dc.date.accessioned2022-08-23T16:26:55Z
dc.date.available2022-08-23T16:26:55Z
dc.date.issued2016-08-05
dc.date.submitted2017-04-20
dc.identifier.citationScience. 2016 Aug 5;353(6299):603-8. doi: 10.1126/science.aaf6803. <a href="https://doi.org/10.1126/science.aaf6803">Link to article on publisher's site</a>
dc.identifier.issn0036-8075 (Linking)
dc.identifier.doi10.1126/science.aaf6803
dc.identifier.pmid27493188
dc.identifier.urihttp://hdl.handle.net/20.500.14038/36665
dc.description<p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractMutations in the optineurin (OPTN) gene have been implicated in both familial and sporadic amyotrophic lateral sclerosis (ALS). However, the role of this protein in the central nervous system (CNS) and how it may contribute to ALS pathology are unclear. Here, we found that optineurin actively suppressed receptor-interacting kinase 1 (RIPK1)-dependent signaling by regulating its turnover. Loss of OPTN led to progressive dysmyelination and axonal degeneration through engagement of necroptotic machinery in the CNS, including RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL). Furthermore, RIPK1- and RIPK3-mediated axonal pathology was commonly observed in SOD1(G93A) transgenic mice and pathological samples from human ALS patients. Thus, RIPK1 and RIPK3 play a critical role in mediating progressive axonal degeneration. Furthermore, inhibiting RIPK1 kinase may provide an axonal protective strategy for the treatment of ALS and other human degenerative diseases characterized by axonal degeneration.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=27493188&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://doi.org/10.1126/science.aaf6803
dc.subjectBiochemistry
dc.subjectCell Biology
dc.subjectCellular and Molecular Physiology
dc.subjectMolecular Biology
dc.subjectNervous System Diseases
dc.subjectNeuroscience and Neurobiology
dc.titleRIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS
dc.typeJournal Article
dc.source.journaltitleScience (New York, N.Y.)
dc.source.volume353
dc.source.issue6299
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/metnet_pubs/33
dc.identifier.contextkey10046366
html.description.abstract<p>Mutations in the optineurin (OPTN) gene have been implicated in both familial and sporadic amyotrophic lateral sclerosis (ALS). However, the role of this protein in the central nervous system (CNS) and how it may contribute to ALS pathology are unclear. Here, we found that optineurin actively suppressed receptor-interacting kinase 1 (RIPK1)-dependent signaling by regulating its turnover. Loss of OPTN led to progressive dysmyelination and axonal degeneration through engagement of necroptotic machinery in the CNS, including RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL). Furthermore, RIPK1- and RIPK3-mediated axonal pathology was commonly observed in SOD1(G93A) transgenic mice and pathological samples from human ALS patients. Thus, RIPK1 and RIPK3 play a critical role in mediating progressive axonal degeneration. Furthermore, inhibiting RIPK1 kinase may provide an axonal protective strategy for the treatment of ALS and other human degenerative diseases characterized by axonal degeneration.</p>
dc.identifier.submissionpathmetnet_pubs/33
dc.contributor.departmentUMass Metabolic Network
dc.contributor.departmentDepartment of Molecular, Cell and Cancer Biology
dc.source.pages603-8


This item appears in the following Collection(s)

Show simple item record